Patient demographics, clinical characteristics, and eribulin treatment characteristics were collected by physicians from the information available in patient medical records.
Clinical outcomes from the initiation of eribulin treatment were assessed. The physician-reported real-world best overall response was abstracted from patient’s medical chart as recorded by the physician at the time of assessment and categorized as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). Real-world progression-free survival (rwPFS) was calculated from the date of eribulin initiation to the earliest date of physician-reported progression or death due to any cause while on eribulin treatment or within 90 days after eribulin treatment discontinuation, as long as no subsequent treatments had been initiated. Patients with no documented progression or death event were censored at 90 days after eribulin discontinuation, start of the new line of therapy, or at the last available follow-up in the medical record, whichever was earliest. Overall survival (OS) was calculated from the date of eribulin initiation to death due to any cause; if no death event occurred, patients were censored at the last available follow-up in the medical record.
Clinical outcomes from the initiation of eribulin treatment were assessed. The physician-reported real-world best overall response was abstracted from patient’s medical chart as recorded by the physician at the time of assessment and categorized as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). Real-world progression-free survival (rwPFS) was calculated from the date of eribulin initiation to the earliest date of physician-reported progression or death due to any cause while on eribulin treatment or within 90 days after eribulin treatment discontinuation, as long as no subsequent treatments had been initiated. Patients with no documented progression or death event were censored at 90 days after eribulin discontinuation, start of the new line of therapy, or at the last available follow-up in the medical record, whichever was earliest. Overall survival (OS) was calculated from the date of eribulin initiation to death due to any cause; if no death event occurred, patients were censored at the last available follow-up in the medical record.
Free full text: Click here
